Insulin therapy <scp>DE</scp> ‐ <scp>intensificAtion</scp> with <scp>iGlarLixi</scp> : A phase 4, open‐label, parallel‐group randomised controlled trial

20250 citationsJournal Articlebronze Open Access

Authors

Insulin therapy simplification from MDI regimen to once-daily iGlarLixi is an efficient and safe treatment option for PwT2D.

Published in: Diabetes Obesity and Metabolism

Volume 28, Issue 3, pp. 1817-1825

Field-Weighted Citation Impact: 0.00